| # | Drug | Count |
|---|---|---|
| 0 | METHOTREXATE SODIUM | 1653 |
| 1 | OXALIPLATIN | 1517 |
| 2 | CYCLOPHOSPHAMIDE | 1426 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 1426 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 1426 |
| 5 | METHOTREXATE | 1407 |
| 6 | AXICABTAGENE CILOLEUCEL | 1381 |
| 7 | DEXAMETHASONE | 1093 |
| 8 | DEXAMETHASONE 1.5 MG | 1093 |
| 9 | TACROLIMUS | 994 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | AXICABTAGENE CILOLEUCEL | 1381 | 0.1359 |
| 1 | LISOCABTAGENE MARALEUCEL | 105 | 0.1199 |
| 2 | BREXUCABTAGENE AUTOLEUCEL | 202 | 0.0936 |
| 3 | IDECABTAGENE VICLEUCEL | 78 | 0.0629 |
| 4 | NELARABINE | 61 | 0.0626 |
| 5 | BLINATUMOMAB | 584 | 0.0545 |
| 6 | PENPULIMAB | 5 | 0.0510 |
| 7 | VANCOMYCIN HYDROCHLORIDE | 308 | 0.0369 |
| 8 | DEXTROSE AND SODIUM CHLORIDE | 6 | 0.0359 |
| 9 | CILTACABTAGENE AUTOLEUCEL | 222 | 0.0338 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 2534 |
| 1 | Nucleoside Metabolic Inhibitor [EPC] | 2437 |
| 2 | Platinum-based Drug [EPC] | 2327 |
| 3 | Alkylating Drug [EPC] | 1856 |
| 4 | Folate Analog Metabolic Inhibitor [EPC] | 1445 |
| 5 | CD19-directed Chimeric Antigen Receptor [EPC] | 1381 |
| 6 | Genetically-modified Autologous T Cells [EPC] | 1381 |
| 7 | Microtubule Inhibitor [EPC] | 1029 |
| 8 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 799 |
| 9 | Azole Antifungal [EPC] | 763 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD19-directed Chimeric Antigen Receptor [EPC] | 1381 | 0.1359 |
| 1 | Interleukin-5 Antagonist [EPC] | 21 | 0.0305 |
| 2 | CD22-directed Immunoconjugate [EPC] | 55 | 0.0184 |
| 3 | Actinomycin [EPC] | 34 | 0.0154 |
| 4 | Aldehyde Dehydrogenase Inhibitor [EPC] | 17 | 0.0150 |
| 5 | CD38-directed Cytolytic Antibody [EPC] | 86 | 0.0147 |
| 6 | Interleukin-6 Antagonist [EPC] | 9 | 0.0139 |
| 7 | Carboxypeptidase [EPC] | 4 | 0.0110 |
| 8 | Benzodiazepine Antagonist [EPC] | 9 | 0.0101 |
| 9 | Antiparasitic [EPC] | 45 | 0.0099 |